Tenax Therapeutics Inc. (TENX)
Symbol Info
Listed Symbol TENX
Name Tenax Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-9.04
Price Info
21 Day Moving Average $1.2467
21 Day EMA $1.284040
50 Day Moving Average $1.2992
50 Day EMA $1.298800
200 Day EMA $1.999140
200 Day Moving Average 1.441790
52 Week High $6.39
52 Week Low $1.03
52 Week Change $-73.694405
Alpha -0.043735
Beta 1.3909
Standard Deviation 0.230433
R2 0.043308
Periods 60
Share Information
10 Day Average Volume 54,094
20 Day Average Volume 120,166
30 Day Average Volume 99,363
50 Day Average Volume 90,396
Outstanding Shares 6,741,860
Float Shares 5,123,321
Percent Float 75.99%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 23
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 676,019
Institute Holdings Percent 15.300000
Institute Sold Previous 3 Months 29,759
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,618,539
Price Change
7 Day Price Change $0.0400000
7 Day Percent Change 3.03%
21 Day Price Change $0.1100000
21 Day Percent Change 8.80%
30 Day Price Change $0.1200000
30 Day Percent Change 9.68%
Month To Date Price Change $0.1500
Month To Date Percent 12.40%
90 Day Price Change $0.040000
90 Day Percent Change 3.03%
Quarter To Date $-0.02
Quarter To Date Percent -1.45%
180 Day Price Change $-0.25
180 Day Percent Change -15.53%
200 Day Price Change $0.130000
200 Day Percent Change 10.57%
Year To Date $0.150000
Year To Date Percent 12.40%
Profile
Description Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The company develops novel product candidates such as Levodimendan IV that have the potential to address various critical care conditions with a high unmet medical need. Its drugs help in the reduction of morbidity and mortality in cardiac surgery patients. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure.
Details
Issue Type CS
Market Cap $9,168,930
Sec Type EQS
Auditor Cherry Bekaert LLP
Total Shares Outstanding 6,741,860
CEO Anthony A. DiTonno
Employees 10
Last Audit UE
Classification
CIK 0000034956
Industry Biotechnology
Sector Healthcare
NAICS Research and Development in Biotechnology (except Nanobiotechnology)(541714)
Info
Address ONE Copley Parkway
Suite 490
Morrisville, NC 27560
Website http://www.tenaxthera.com
Facisimile +1 919 855-2133
Telephone +1 919 855-2100
Email jesse@sternir.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-393,910
Price To Sales -
Price To Free Cash -1.2
PE High Last 5 Years -
Price To Book 1.0
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 1.0
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 10.0
Leverage Ratio 1.1
Quick Ratio 9.5
Long Term Debt To Capital 0.01
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -175.17
Return On Equity -196.82
Return On Capital -189.06
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
TENX
Tenax Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.